Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...
GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact daily functioning. This analysis assessed how functional and structural ...
Using a new imaging technique, researchers from the National Eye Institute have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these ...
NEW YORK CITY -- Subretinal drusenoid deposits (SDD) had a significant association with underlying cardiovascular disease (CVD), adding a missing link between age-related macular degeneration (AMD) ...
A recent retrospective cross-sectional observational study concluded that the Medios AI system, in conjunction with the Remidio smartphone-based fundus camera, has strong potential to ...
Three days after the August solar eclipse, a young woman presented to New York Eye and Ear Infirmary of Mount Sinai in New York City with classic symptoms of solar retinopathy, which is a rare form of ...
Please provide your email address to receive an email when new articles are posted on . Tinlarebant reduced lesion growth rate by 35.7%. The drug was well tolerated throughout the trial. Belite Bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results